AUS
NZ
UK
CA
USA
IND
Highlights
- ResMed steadied as durable sleep and respiratory demand set it apart from the sector's sentiment swings.
- Recurring device and consumable revenue offered a growth profile grounded in fundamentals.
- Peers in respiratory care, wound repair and protection shared the sector's firmer tone.
ResMed (ASX:RMD) held a steady tone today as durable demand for sleep and respiratory care set it apart from the sentiment-driven swings sweeping the broader healthcare sector. While much of the recent recovery in the space has looked like a rotation back into beaten-down names, the sleep-technology group has leaned on genuine underlying growth, with rising demand for its devices and the recurring revenue that follows.
Sleep demand anchors the story
At the core of the group sits a large and growing market for the treatment of sleep-disordered breathing. Awareness of conditions such as sleep apnea has risen steadily, diagnosis rates continue to climb, and the pool of people seeking treatment keeps expanding, giving the business a structural tailwind independent of the economic cycle.
That demand translates into a dependable stream of device sales, and crucially into the recurring revenue from masks, accessories and consumables that patients replace over time. It is that razor-and-blade dynamic, where an installed base generates ongoing sales, that gives the earnings a resilience and visibility many healthcare peers would envy.
Growth grounded in fundamentals
What distinguishes the group from much of the sector's recent rebound is that its recovery rests on fundamentals rather than sentiment. Revenue and earnings have continued to grow through the macro turbulence, confirming that the underlying business remained healthy even as the share price swung with the broader mood.
That distinction matters. Where many healthcare names have bounced simply because they were sold down too far, the sleep-technology group can point to genuine operating momentum. A recovery underpinned by rising revenue is inherently more durable than one driven purely by a shift in sentiment, and the market has begun to reward that difference.
Respiratory peers share the tone
The firmer tone extended to others in respiratory care. Fisher & Paykel Healthcare (ASX:FPH), which makes respiratory and acute-care devices, occupies an adjacent niche with its own structural demand drivers, from hospital ventilation to home respiratory support.
Both sit among the ASX Healthcare Stocks whose demand is grounded in clinical need rather than discretionary spending, giving them a steadier footing than more cyclical corners of the market.
Recurring revenue smooths the cycle
The recurring nature of consumable revenue is one of the sector's most attractive features. Once a device is in use, the patient returns regularly for replacement parts, creating a predictable, annuity-like income stream that grows as the installed base expands.
That predictability is precisely what the market values in uncertain times. It reduces reliance on winning new sales each period and builds a compounding base of revenue that tends to grow steadily year after year. For businesses with large and expanding installed bases, that dynamic underpins both the resilience and the long-run growth of earnings.
Innovation keeps the edge sharp
Staying ahead in medical devices demands constant innovation, and the leading names invest heavily to keep their technology at the frontier. New device generations, digital health features and connected-care platforms all help defend market share and open new avenues of growth.
That investment is a moat in itself. Rivals face the challenge of matching not just the hardware but the clinical evidence, regulatory approvals and physician relationships that come with an established product. The names that keep innovating tend to widen their lead, turning technological advantage into durable commercial strength.
Wound care adds another angle
The sector's breadth extends into specialised areas such as wound repair. PolyNovo (ASX:PNV), which develops regenerative technology for treating severe wounds and burns, illustrates how a focused innovator can build a growth story around a distinct clinical need.
Such names carry a different risk-and-reward profile, more dependent on the adoption of a specific technology than on broad demographic trends. But they add texture to the healthcare landscape, and their progress shows how the sector spans everything from mass-market sleep therapy to highly specialised regenerative medicine.
Protection and hospital supply
Further along the spectrum sit the suppliers of protective and hospital products. Ansell (ASX:ANN), a maker of protective gloves and safety equipment used across healthcare and industry, offers exposure to the steady, high-volume demand for the everyday consumables that clinical settings rely on.
The currency shapes reported results
For healthcare exporters, the currency is a constant companion. With much of their revenue earned offshore, a softer Australian dollar flatters reported results while a stronger one trims them, adding translation noise to the underlying performance.
Operational execution, disciplined capital management and clear project delivery remain central as the Australian market continues assessing this part of the listed sector.
